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ABSTRACT
Background: CDK4/6 inhibitors are the new standard of care in hormonal receptors positive (HR+) advanced 
breast cancer (ABC). Phase III trials demonstrated an improvement in survival outcomes in patients with combined 
endocrine approach compared to endocrine therapy (ET) alone. The aim of this retrospective study was to assess 
prognostic factors for clinical response to CDK4/6 inhibitors.
Methods:  All patients receiving CDK4/6 inhibitors from September 2016 to July 2019 were registered in a database. 
Data on tumor and patient’s characteristics as well as concomitant medications were collected. Survival data were 
analyzed by Kaplan Meier curves and log rank test. Treatment toxicities were graded according to CTCAE v5. A 
drug-drug interactions analysis among CDK 4/6 inhibitors and co-administered medications was performed too.
Results: 121 patients were included in the study: 49% of patients treated in 1st -line, 25% in 2nd -line and 26% 
in 3rd –or further lines. 1st-line objective response rate (ORR) and clinical benefit rate (CBR) was 56% and 68%, 
compared to 40% and 50% in 2nd-line and 31% and 47% in heavily pre-treated patients, respectively. Median PFS 
according to line setting was: not reached in 1st-line, 17 months (95% CI 13-21) in 2nd-line and 7 months (95% CI 
4-12) in 3rd or further lines. Negative prognostic factors in term of PFS were: previous chemotherapy for metastatic 
disease (p=0.0001), visceral metastatic sites (p=0.002) and endocrine sensitivity (p=0.001). No association among 
concomitant drugs administered and survival outcome was found. 94% of patients experienced neutropenia (G3-G4 
60%) with 3% of febrile neutropenia. 71% of patients treated with Abemaciclib had diarrhea. Management of AE 
included 63% of treatment delay, 44% of 1st dose reduction and 15% of 2nd dose reduction, all due to neutropenia. 
No treatment discontinuation due to any toxicity was observed.
Conclusion: Data on efficacy and safety profile of CDK 4/6 inhibitors administered outside the context of a clinical 
trial are consistent with those reported in Phase III trials. Previous chemotherapy for metastatic disease, visceral 
metastatic site as well as previous endocrine sensitivity negatively affect CDK 4/6 inhibitors efficacy. Concomitant 
medications did not affect survival outcome or safety profile.
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INTRODUCTION
In recent years, CDK 4/6 inhibitors have become the standard of 
care in hormonal receptor positive HER2 negative (HR+/HER2-) 
Advanced Breast Cancer (ABC) on the basis of survival benefits 
from Paloma, Monaleesa and Monarch Phase III Trials [1-6]. CDK 
4/6 inhibitors plus Endocrine Therapy (ET) compared to ET alone 
double up survival outcomes in first line setting as well as after 
aromatase inhibitors failure [7,8]. Due to these impressive results, 
the majority of patients with HR+/HER2- disease are candidate to 
CDK 4/6 inhibitors as part of their treatment. 
In this study, we retrospectively collected clinical-pathological and 
prognostic data on HR+/HER2- BC patients treated with CDK4/6 
inhibitors at the University Hospital of Modena in order to identify 
significant prognostic factors.
PATIENTS AND METHODS
Patient population and treatment
Electronic medical records of all patients treated with CDK4/6 
inhibitors for ABC in Modena Cancer Center from September 
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2016 to July 2019 were retrospective reviewed and collected.
All patients with a histologically proven diagnosis of HR+/HER2- 
BC treated with CDK 4/6 inhibitors plus endocrine-therapy 
based on standard guidelines were included. HR+/HER2- BC was 
defined as estrogen and/or progesterone receptors expression >1% 
and HER2 negative (score 0 or 1+ or ISH negative). Palbociclib, 
Ribociclib or Abemaciclib were administered according to Italian 
prescription status. Type of CDK 4/6 inhibitor, dose reductions/
delays or drug discontinuation were applied and recorded as 
for clinician’s judgement. Medical records were retrieved for 
demographic, clinical and molecular features of the disease, previous 
treatments and related outcomes, number and site of metastases at 
the time of CDK 4/6 inhibitor starting, objective response, date of 
disease progression and date of last follow-up or death. According 
to the duration of previous endocrine response, each patient was 
classified as endocrine sensitive (if relapsed at least 12 months after 
the completion of adjuvant endocrine therapy or with de novo 
ABC), primary resistant (if relapsed within 24 months while on 
adjuvant endocrine therapy or progressing within 6 months while 
on first-line endocrine therapy for advanced disease) or secondary 
resistant (if relapsed after 24 months of adjuvant endocrine therapy 
or within 12 months after ending adjuvant endocrine therapy or 
with a progression disease after at least 6 months of endocrine 
therapy for advanced disease) [15]. 
Concomitant medications, known to be potentially agonist or 
antagonist of CDK 4/6 inhibitors, were collected too. Considering 
their pharmacodynamics and pharmacokinetics, concomitant 
drugs were classified as CYP3A4 inducers or CYP3A4 inhibitors 
or CYP3A4 major substrates or Membrane transporter substrates 
[13,14]. A list of concomitant medications is available in 
supplementary material Table1 bis.
Table 1: Baseline characteristics for all patients included for analysis.
Patients n°121 (%)
  Median age 52 yrs (25-88)
Endocrine sensitivity
  Endocrine sensitive 48 (40)
  Primary resistance 16 (13)
  Secondary resistance 57 (47)
  No concomitant medications 32 (26)
  Concomitant medications 89 (74)
  Cyp 3A4 Inducers 7 (8)
  Cyp 3A4 Inhibitors 9 (10)
  Major Cyp 3A4 substrates 66 (74)
  Membrane transporter substrates 7 (8)
Neoadjuvant/adjuvant chemotherapy 63 (52)
Adjuvant Endocrine therapy 72 (59)
  Tamoxifen 26 (36)
  Aromatase inhibitors (Ais) 21 (29)
  Exemestane 11 (15)
  Tamoxifen switch to Ais 14 (19)
Chemotherapy for MBC 31 (26)
Endocrine therapy for MBC
Previuos Exemestane
 plus Everolimus 
31 (26)
9(7)





Aromatase inhibitors 53 (44)
Fulvestrant 68 (56)
Treatment efficacy was evaluated according to RECIST criteria 
by CT and bone scan or PET/CT scan every 3-6 months, as for 
standard practice. Objective Response Rate (ORR) (defined as 
the percentage of patients with complete or partial response) and 
Clinical Benefit Rate (CBR) (defined as the percentage of patients 
with complete or partial response or stable disease for at least 6 
months) were assessed too. 
Toxicity was graded according to Common Terminology Criteria 
for Adverse Events (CTCAE v5). 
The study was approved by the local Ethic Committee and 
conducted in accordance with the Helsinki Declaration. All 
  Histology  
  Ductal 85 (70)
  Lobular 27 (22)
  Other 9 (7)
  Nuclear Grade  
patients released a written informed consent.
Statistical analysis
Variables were assessed by Pearson Chi-Square test or Fisher Exact 
test. Their impact on survival was tested in Cox uni/multivariate 
models. The multivariate Cox hazard model was built using stepwise 
regression (forward selection). Enter and remove limit were p=0.10 
and p=0.15. The following variables were considered: previous 
systemic treatment, sensitivity to ET, type and number of metastatic 
sites. Survival outcomes of interest were Progression Free Survival 
(PFS: defined as the time from the date of the diagnosis to the date 
of the first documented relapse) and Overall Survival (OS: defined 
as the time from diagnosis of BC to death/last follow up). Survival 
was addressed by the Kaplan–Meier method and log-rank test. 
Significance was defined at p ≤ 0.05 level. The Cox proportional 
 1-2 46 (38)
 3 28 (23)
 Unknown 47 (39)
  Ki67% x
  ≤20% 78 (64)
  >20% 30 (25)
  Unknown 13 (11)
Stage at diagnosis
  Early Breast Cancer 87 (72)
 Metastatic Breast Cancer 34 (28)
Metastatic sites
  Visceral 61 (51)
  Non visceral 60 (49)
Number of metastatic sites
 1 44 (36)
 2 45 (37)
 ≥3 32 (26)
hazard model was used to estimate Hazard Ratios (HR).
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RESULTS
Patients and treatment characteristics
Overall, 121 patients diagnosed with HR+/HER2- ABC and treated 
with CDK 4/6 inhibitors from September 2016 to July 2019 in 
Modena Cancer Center were detected. Main patients and tumors 
characteristics are summarized in Table 1. In brief, median age was 
52 years (25-88 years). More than half of patients received previous 
neo-/adjuvant chemotherapy. Adjuvant endocrine therapy was 
suggested in 72 women (59%), 45% of them received an aromatase 
inhibitor. Forty-eight (40%) patients were classified as endocrine 
sensitives, 16 (13%) as primary resistants and 57 (47%) as secondary 
resistants. Eight-seven patients (72%) experienced a relapse, with 
a median disease-free interval of 9.5 years (from 4 months to 30 
years), being the other 34 patients (28%) diagnosed with de novo 
ABC. At treatment starting, 51% of patients had visceral disease; 
in particular, 63% had two or more metastatic sites. Seventy-four 
per cent of patients received concomitant medications, mainly 
major CYP3A4 substrates that could potentially increase CDK 4/6 
activity and/or toxicity (Table 1 bis). Eighty-three per cent of women 
received Palbociclib as CDK 4/6 inhibitor, followed by Ribociclib 
(11%) and Abemaciclib (6%); plus an aromatase inhibitor in 53 
patients (44%) or fulvestrant in 68 (56%) cases (Table 1). Forty-
nine per cent of patients was treated in 1st line, 25% in 2nd line 
and 26% in 3rd or further lines (Table 2). Previous treatment with 
Second-line setting - The ORR was 40%. A stable disease was 
recorded in 10 % of these patients. Overall, the CBR was reported 
in 15 patients (50%). Median PFS of 17 months (CI 13-21 months) 
was calculated (Table 2).
Third- or further lines – Overall, the ORR was 31%. A stable disease 
was recorded in 16% of these patients. The CBR was observed in 
15 patients (47%). Median PFS of 7 months (95% CI 4-12 months) 
(Table 2). In particular, five heavily pretreated patients (more than 
5 lines of treatment for metastatic disease) stayed on CDK4/6 
inhibitors for at least one year. 
Considering clinical-pathological and prognostic data collected, 
chemo pre-treated patients showed a significant reduction in 
PFS compared to chemo-naïve ones (p₌ 0.0001) (Figure 1A). 
Furthermore, endocrine sensitive patients had significant longer 
PFS compared to endocrine resistant ones (p=0.001) (Figure 1B). 
Site of metastasis influenced the treatment efficacy too. Patients 
without visceral disease had prolonged PFS compared to those 
with visceral metastasis (mPFS Not reached vs 9 months, p₌0.002) 
(Figure 1C). Multivariate analysis confirmed these results (Table 3). 
No significant differences were observed in median PFS according 
everolimus plus exemestane was administered in 9 patients (7%).
Efficacy
Overall, the median duration of CDK 4/6 inhibitor treatment was 
21 months (95% CI 18,1 to 23,9 months). At the time of analysis, 
49 patients had progressed on CDK 4/6 inhibitors and 14 died 
for BC. Median OS was not reached with 77% of patients alive 
at 5 years from the diagnosis of metastatic disease. As expected, 
efficacy of CDK 4/6 inhibitors significantly decreased according 
to the number of previous lines of treatment for metastatic disease. 
First-line setting -The ORR was 56% with 6 cases of complete 
response. A stable disease was recorded in 10% of these patients. 
Overall, the CBR was observed in 40 patients (68%). At the time of 
the analysis, median PFS was not yet reached, and 65% of patients 
Figure 1a: Process of inclusion of Patients for the Study.
were still on treatment at 24 months of follow up (Table 2).
N° pts (%)
mPFS (months) (95% 
CI)
p value ORR (%) CBR (%)
Age classes 
< 35 years 5  17 (11-18)
0.981
80 100
36 -65 years 84 19 (17-24) 44 57
> 65 years 32  19 (12-19) 44 53
Nuclear grade
1-2 46 19 (17-26)
0.223
52 63
3 28 13 (10-17) 36 61
Ki 67%
≤ 20% 78 Not reached
0.135
47 63
>20% 30 18 (13-20) 40 47
Stage at the diagnosis
Early breast cancer 87 17 (14-19)
0.722
44 59
Advanced breast cancer 34 Not reached 50 56
to concomitant medications. 
Table 2: PFS, ORR, CBR of CDK4/6 inhibitors.
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Table 3: Multivariate analysis of clinical-pathological factors for PFS.
 HR 95% CI p
Previous chemotherapy (no vs yes) 1.93 1.53 - 3.53 0.032
Endocrine resistant (no vs yes) 2.67 1.31 - 5.41 0.006
Visceral disease (no vs yes) 2.06 1.12 – 3.78 0.019
N. of metastatic sites (1 vs > 2) 1.03 0.54 - 1.94 0.922
Abbreviations: HR: Hazard Ratio; IC: Confidence Interval; PFS: 
Progression Free Survival
Safety profile
In this patient population, data on toxicity confirmed CDK 
4/6 inhibitors-related neutropenia as the most common adverse 
event (94% all grades and 60% Grade 3-4) with only 3% of cases 
of febrile neutropenia. All reported adverse events are listed in 
Table 4. The most common gastro-intestinal adverse event was 
diarrhea (12% of cases), in most cases in patients on Abemaciclib. 
Neither dose reduction nor discontinuation was applied due to 
diarrhea. All other toxicities were graded 1-2. Overall, no treatment 
discontinuation for AE was observed. Management of AE included 
CDK 4/6 inhibitors treatment 
line
  1st 59  Not reached
0.0001
56 68
  2nd 30 17 (13-21) 40 50
  3rd or further lines 32  7 (7-14) 31 47
Previous adjuvant endocrine 
therapy  
Tamoxifen 26 13 (22-20)
0.675
46 54
Aromatase inhibitors 35 Not reached 33 52
Exemestane 11 12 (9-20) 45 64
Previous chemotherapy 
exposure  
Chemo-naïve 31  Not reached 
0.0001
32 45 
Chemo-pretreated 31 7 (4-12) 39          52
Endocrine sensitivity
Endocrine sensitive 48    Not reached
0.001
60          73
Primary resistance 16       8 (2-11) 25          44
Secondary resistance 57       12 (7-17) 39          49
Number of metastatic sites
1 44 Not reached
0.011
48 70
2 45 15 (13-20) 51 55
> 3 32 12 (9-20) 34 44
Site of metastasis
Visceral disease 61 9 (6-19)
0.002
44          49
Non visceral disease 60 Not reached       47          67
Concomitant medications
No concomitant drugs 32 15 (14-25) 
0.913 
44 53
Drugs that increase Cyp 3A4 
activity
82 Not reached 45 61
Drugs that decrease Cyp 3A4 
activity
7  Not reached 57 57
Abbreviations: N: Number; pts: Patients; mPFS: Median Progression Free Survival; CI: Confidence Interval; ORR: Objective Response Rate; 
CBR: Clinical Benefit Rate
treatment delay in 63% of cases, one-dose reduction in 44% and 
two-dose reductions in 15%. All the dose/treatment adjustments 
were due to neutropenia. No significant difference in AE was 
observed among subgroups of patients treated with concomitant 
Figure 1b: Kaplan-Meier curves of PFS according to previous endocrine 
sensitivity. Abbreviations: mPFS: Median Progression Free Survival
Figure 1c: Kaplan-Meier curves of PFS according to previous metastatic 
sites. Abbreviations: mPFS: Median Progression Free Survival
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medications compared to patients with no concomitant drugs 
(Supplementary material Table 2).
Table 4: Adverse events.





   Anemia 46 1 1
   Thrombocytopenia 56 1 0
No Haematological AE 
 Diarrhea 
12 0 0
   Nausea 9 0 0
   Vomiting 6 0 0
   Abdominal pain 8 0 0
   Hypertransaminasemia 48 3 0
   Xerosis 20 0 0
   Arthralgia 11 0 0
   Alopecia 9 0 0
   Appetite loss 7 0 0
   Pruritus 4 0 0
   Fatigue 38 0 0
Abbreviations: AR: Adverse events
DISCUSSION
CDK 4/6 inhibitors approval has significantly changed the 
therapeutic algorithm of patients with HR+/HER2- ABC [1-6]. 
Paloma, Monaleesa and Monarch trials suggested that CDK4/6 
inhibitors plus ET are more active than ET alone in all patients 
in both PFS and OS. An extended follow up analysis of Paloma 
2 trial confirms the double up PFS advantage from the use of 
Palbociclib plus letrozole compared to ET alone in 1st line setting 
(p<0.0001) [16]. Similar data have been reported from Monaleesa 
2 and Monarch 3 trials (Ribociclib plus ET median PFS 25.3 
months vs 16 months; Abemaciclib plus ET median PFS 28.18 
months vs 14.76 months, respectively) [3,4]. Statistically significant 
and clinically relevant advantages in OS were reported too [2,5,8]. 
The magnitude of benefit in OS showed in Monaleesa -3 and -7 
and Monarch 2 studies was remarkable consistent: Ribociclib plus 
Fulvestrant median OS 40.2 vs 32.5 months, Ribociclib plus ET 
in premenopausal women OS rate 70.2% vs 46% at 42 months 
and Abemaciclib plus Fulvestrant median OS 46.7 months vs 37.3 
months, respectively [2,5,8]. Recent data from real world experiences 
confirmed the efficacy and safety of CDK4/6 inhibitors even in un-
selected population [9-11]. Results from our retrospective collection 
further support their efficacy. Considering first and second line, 
mPFS, ORR and CBR are consistent with those reported in 
registrative clinical trials [1-6]. Convincing benefit has been seen in 
heavily pretreated patients too, with a 47% of CBR and mPFS of 7 
months. Evidence from two real world studies published on heavily 
pretreated population reporter a shorter mPFS compared to our 
data (4.5 months and 3.2 months, respectively). This discordance 
could be justify by the different definition of heavily pretreated 
patients, defined as patient treated in third or further line in our 
study population versus patients with at least four lines of systemic 
treatment in literature [19,20].
Despite the high rate of efficacy reported, clinical experience 
suggested that some patients benefit less from this class of drugs. 
The primary aim of our study was to clarify which clinical factors 
could be prognosticators for CDK 4/6 inhibitors. In particular, 
previous chemotherapy treatment for ABC, visceral disease and 
endocrine resistance were independent negative prognostic factors 
in term of PFS for women on CDK 4/6 inhibitors. In particular, 
chemo pre-treated patients had a mPFS of 7 months, compared 
to more than 50% of the chemo-naïve patients still on treatment 
at two years (Figure 1A). This finding can be explained by the fact 
that patient with HR+ disease treated with chemotherapy had more 
aggressive diseases from the beginning. Site of metastasis influenced 
the treatment efficacy too. Activity of CDK4/6 inhibitors was 
higher in patients without visceral involvement with a mPFS Not 
reached vs 9 months (Figure 1C, p=0.002). The predictive value of 
site of metastasis was concordant with those reported in the real 
world study by Pizzuti L. et al. Fifty-nine per cent of the patients 
without visceral disease was still on treatment at 1 year compared 
to 29.5% of those with visceral involvement, p=0.001 [12]. As 
expected, endocrine sensitive patients had significant better PFS 
compared to endocrine resistant ones (Figure 1B, p=0.001).
Regarding concomitant medications known to be inducers 
or inhibitors of CYP3A4, we performed an analysis in order to 
identify their possible interactions with CDK 4/6 inhibitors 
activity/toxicity. All CDK 4/6 inhibitors are major substrates 
for CYP3A4. In particular, they are inhibitors of CYP3A4 and 
the co-administration of them with strong or moderate CYP3A4 
inhibitors may increase their AUC and, consequently, their risk of 
toxicity [13]. In our study, we classified concomitant medications as 
CYP3A4 inducers, CYP3A4 inhibitors, Major CYP3A4 substrates 
and Membrane transporter substrates. Based on our data, no 
significant differences were observed in term of toxicity or efficacy 
according to concomitant medications.
Data from clinical trials showed a favourable safety profile with quite 
manageable side effects [1-6]. Patient quality of life is maintained 
under therapy and, particularly in later line settings too [21-23]. 
The toxicity analysis confirmed a good tolerance to CDK 4/6 
inhibitors without treatment discontinuation for AEs. Neutropenia 
was the most common haematological toxicity for palbociclib and 
ribociclib (95%-100% all grade with and 56%-71% of G3-4). As 
expected, Abemaciclib has a lower incidence of neutropenia with 
no G3-4 cases but a greater incidence of diarrhea compared to other 
CDK4/6 inhibitors (7%-9% Ribociclib/Palbiclib vs 71% with 
Abemaciclib). Despite that, no treatment discontinuation related 
to diarrhea was observed, probably due to the prompt intervention 
with antidiarrheal drug in case of symptoms.
Our study has some limitations. First, the small sample size and the 
length of follow up that was relatively short and overall insufficient 
to draw conclusions in terms of OS. The results of this analysis 
must be interpreted in light of multiple biases and weaknesses 
mainly, though not exclusively, stemming from its study design, i.e., 
retrospective, observational design. Despite that our analysis has 
relevant strengths, it provides evidence in support of the activity 
CDK 4/6 inhibitors in real-world practice, even in heavily pre-
treated women.
CONCLUSIONS
CDK 4/6 inhibitors outside a context of clinical trial are safe, 
well tolerated, with a good efficacy, consistent with that reported 
in clinical trials. Previous chemotherapy for metastatic, visceral 
disease and endocrine resistant BC negatively affects CDK 4/6 
inhibitors sensitivity. Co-administration of drug that is known to 
be substrates for CYP3A4 did not increase CDK4/6 inhibitors 
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toxicity or reduce efficacy.
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